Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CL...
Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA
9 Dec 2020
Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
9 Dec 2020
ASH 2020: Targeted therapies in r/r multiple myeloma
Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar
8 Dec 2020
Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment
Prof Monica Bocchia - University of Siena, Siena, Italy
8 Dec 2020
Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve se...
Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA
8 Dec 2020
Treating acute leukaemias of ambiguous lineage
Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Ho...
8 Dec 2020
Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China...
Dr Shaji Kumar and Dr Wenming Chen
8 Dec 2020
First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T31...
Dr Jorge Cortes - Augusta University, Augusta, USA
8 Dec 2020
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combina...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
8 Dec 2020
Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin l...
Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia
8 Dec 2020
Five year update of ECHELON-1 for classical Hodgkin lymphoma
Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil
8 Dec 2020
Off-the-shelf multi-virus specific T cells following haematopoietic stem cell tr...
Dr Bilal Omer - Baylor College of Medicine, Houston, USA
8 Dec 2020
